Patients with chest tube after lung cancer radical operation.
Conditions
Interventions
Lidocaine hydrochloride jelly 20mg/1ml Lidocaine hydrochloride cream 70mg/1ml
Pracebo (sterilized jelly)
Sponsors
Department of Chest, Breast and Endocrinologic Surgery, Akita University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Shall meet the followin: 1) The case has been received a lung cancer radical operation and patients between 20 to 79 years of age. 2) The outstanding cases of enforced chemoradiationtherapy for lung cancer. 3) Performance Status (ECOG) of 0-1, and The American Society of Anesthesiologists physical status 0-1. 4) The outstanding cases of diabetes. 5) has the following organ function, adequate bone marrow, liver and renal function patients are kept White blood cell count >and= 3,000 / mm3 Neutrophil count >and= 1,500 / mm3 Platelet count >and= 100,000 / mm3 hemoglobin >and= 9.5g/dL AST / ALT; Less than 2.5 times the upper limit of normal facility Total Bilirubin <and= 1.5mg / dL Serum creatinene; more than 1.5 times the upper limit of normal SpO2 (Room air) 90% (PaO2 65mmHg or more) Less than 1+ proteinuira 6) At the time of the start date of administration, the patient has the following period has elapsed from prior treatment (1) radiation therapy For non-radiation to the chest: Longer than two weeks from the date of last exposure (2)surgical procedure (including pleurodesis) Without surgery lobectomy (include thoracotomy) 4 or more weeks Finish treatment (pleurodesis) more than two weeks 7) received a description of the contents of this trial, patient consent was obtained from the documents themselves
Exclusion criteria
Exclusion criteria: But if any one of the following will be excuded. 1) radiotherapy (radiation to the chest than excluded) 2) chemotherapy 3) patients with previously untreated brain metastasis 4) patients with infectious diseases and clinical problems 5) interstital pneumonia, pneumonitis, radiation pneumonitis, pulmonary infections, pulmonary fibrosis, patients have been complicated by pneumonia and other pulmonary disorder drug 6) clinical problems and complications (abnormal electrocardiogram, cardiac dysfunction, arrhythemias, and sever heart disease), patients with 7) patients with diabetes 8) patients with a large amount of ascites cardiac effusion pleural effusion 9) activity in patients with cancers 10) patients with a history of severe drug allergy 11) in patients who are pregnant or potentially pregnant lactating 12) In addition, patients were deemed unsuitable for the safe conduct of the study doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wound pain and pain of extubation thoracic tube. | — |
Countries
Japan
Contacts
Public ContactNobuyasu Kurihara
Akita University Graduate School of Medicine Department of Chest, Breast and Endocrinologic Surgery
Outcome results
None listed